JALMARTI
Live / Applied — First extension granted (statement of use) (as of 22 Nov 2025)
What this means for you
Not registered yet, but its 16 Apr 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98502296
- Mark type
- Stylized text
- Filed
- 16 Apr 2024
- Published for opposition
- 01 Apr 2025
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prior registrations
Prosecution history
- 23 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Nov 2025 — SOU EXTENSION 1 GRANTED
- 22 Nov 2025 — SOU EXTENSION 1 FILED
- 22 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 27 May 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 01 Apr 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Apr 2025 — PUBLISHED FOR OPPOSITION
- 26 Mar 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 05 Mar 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 04 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 04 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 06 Nov 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 06 Nov 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 26 Sept 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED